Many patients <12 years of age experienced zero bleeds during a mean treatment duration of 7.7 months on RIXUBIS® prophylactic treatment1,3

In the pediatric study, the prophylactic efficacy of RIXUBIS was studied in 23 previously treated patients (PTPs) between 1.8 and 11.8 years with severe or moderately severe hemophilia B for a mean treatment duration of 7.7 ± 1.08 months.1,3

39%
of patients experienced zero bleeds on RIXUBIS prophylaxis1,3
  • A recombinant factor IX indicated for routine prophylaxis to treat children and adults with hemophilia B1

Selected Important Risk Information for RIXUBIS [Coagulation Factor IX (Recombinant)]

You should not use RIXUBIS if you are allergic to hamsters or any ingredients in RIXUBIS.

Allergic reactions have been reported with RIXUBIS. Call your healthcare provider or get emergency treatment right away if you get a rash or hives, itching, tightness of the throat, chest pain or tightness, difficulty breathing, lightheadedness, dizziness, nausea, or fainting.

Common side effects that have been reported with RIXUBIS include: unusual taste in the mouth, limb pain, and atypical blood test results.

Please see RIXUBIS Indications and Detailed Important Risk Information.


Know Your Annual Bleed Rate (ABR)

Annual bleed rate is the number of bleeds a person experiences over the course of one year. If you don't have a year's worth of bleeds tracked, simply take the number of bleeds that you had in the last month and multiply by 12 as an estimate, which is your annualized bleed rate (ABR).

RIXUBIS achieved a low ABR in clinical study results when used in routine prophylactic treatment in patients <12 years of age1

RIXUBIS delivered results by treating most bleeds in children <12 years of age1

The efficacy of RIXUBIS was evaluated in a pediatric study, in which a total of 23 male PTPs between 1.8 and 11.8 years of age (mean age 7.10 years), with 11 subjects <6 years of age, received RIXUBIS for routine prophylaxis and control of bleeding episodes.1

89 of bleeds
were treated with just 1 to 2 infusions of RIXUBIS
96 of bleeding episodes
were rated by patients as having excellent or good bleed resolution with RIXUBIS

Excellent is defined as full relief of pain and cessation of objective signs of bleeding after a single infusion; no additional infusion is required for the control of bleeding; Good is defined as definite pain relief and/or improvement in signs of bleeding after a single infusion; possibly requires more than one infusion for complete resolution.1

RIXUBIS incremental recovery in previously treated patients <12 years of age1

0.7IU/dL
is the average incremental
recovery level of RIXUBIS

Mean incremental recovery for RIXUBIS 30 minutes after infusion at trial completion/termination.

Know Your Recovery

After an infusion, your doctor may measure or keep track of the amount of factor IX in your blood. One such measure is called incremental recovery, or simply, recovery. Recovery is important to know because it helps your doctor determine the proper dose of factor your body needs.

Recovery is measured by taking a blood test, also called an assay. Recovery is different for every person and may change for you over time. It can be influenced by age and weight and differs based on the factor product used.4-7

RIXUBIS [Coagulation Factor IX (Recombinant)] news

News and updates

SIGN UP
You may be eligible to try RIXUBIS [Coagulation Factor IX (Recombinant)] for free today

See if you are eligible to try RIXUBIS® for free today

GET STARTED
Help with RIXUBIS [Coagulation Factor IX (Recombinant)] cost

Need help paying for RIXUBIS?

LEARN MORE
Meet your local representative

Meet your local representative

CONNECT